Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 2, 2025

Emerging Data for Odronextamab in DLBCL

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, John Allan, MD, Tara Graff, MD

Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.

Episodes in this series

EP. 1 ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP. 1 ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP. 2 Emerging Data for Odronextamab in DLBCL

EP. 2 Emerging Data for Odronextamab in DLBCL

EP. 3 Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP. 3 Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP. 4 Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP. 4 Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP. 5 ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP. 5 ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP. 6 MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP. 6 MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP. 7 Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP. 7 Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP. 8 Key Strategies for Preventing CRS and ICANS

EP. 8 Key Strategies for Preventing CRS and ICANS

EP. 9 Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP. 9 Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP. 10 Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP. 10 Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP. 11 Successful Implementation of Bispecific Therapies: Expert Recommendations

EP. 11 Successful Implementation of Bispecific Therapies: Expert Recommendations

EP. 12 Benefits of Implementing Bispecific Therapies in the Community

EP. 12 Benefits of Implementing Bispecific Therapies in the Community

EP. 13 Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP. 13 Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP. 14 Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

EP. 14 Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

Video content above is prompted by the following:

What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home

Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS

Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship

New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease

CAR T Therapy Likely the Next Frontier for Treating Patients With MG: James F. Howard, MD